NovImmune SA – Product Pipeline Review – 2012

Introduction

Global Market Direct’s pharmaceuticals report, “NovImmune SA - Product Pipeline Review - 2012” provides data on the NovImmune SA’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, NovImmune SA’s corporate website, SEC filings, investor presentations and featured press releases, both from NovImmune SA and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- NovImmune SA - Brief NovImmune SA overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of NovImmune SA human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of NovImmune SA with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the NovImmune SA’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Highlights

Reasons to buy

- Evaluate NovImmune SA’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of NovImmune SA in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the NovImmune SA’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with NovImmune SA.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of NovImmune SA and identify potential opportunities in those areas.